Total Funding
60
33
Total FundingPost-IPO Equity raised
Growth Score
-7 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
136133
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
- Leslie Sloan: Chief Operating Officer
- Scott W Rowlinson: VP Research & Development
About the Company
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that address rare genetic diseases.
